September 25, 2017
College Park Marriott / Hyattsville, MD

Organizers

The Lupus PFDD meeting is being organized jointly by the Lupus and Allied Diseases Association, the Lupus Foundation of America and the Lupus Research Alliance. All three organizations are full and equal partners in this collaboration that aims to benefit the entire lupus community.

Below, please find brief descriptions of each organization along with links to each organization’s website

The Lupus and Allied Diseases Association, Inc., was founded in 1978 and is a national non-profit organization dedicated to enhancing quality of life for those impacted by lupus and allied diseases and other conditions of unmet need by fostering collaboration among stakeholders and promoting innovative advocacy, education, awareness and biomedical research programs. As a passion-driven, patient-focused association led by individuals with lupus and their loved ones, it is our goal to improve access to care and quality of life by supporting initiatives that lead to the discovery of better diagnostics, superior treatments, causes and cures.

The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world’s cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus.

The Lupus Research Alliance unites the global lupus community in bold determination to free the world of lupus through the power of science. We will transform the lives of people affected by lupus as we welcome and embrace a new scientific era, pioneer innovation, push the frontiers of knowledge, enlist diverse new scientific talent and lead the drive to new treatments, prevention and cure. Because the board of directors funds all of the organization’s administrative and fundraising costs, 100 percent of all public donations go directly to funding research programs.

The meeting content and format were developed solely for the purpose of the Lupus PFDD Initiative; a collaboration between the Lupus and Allied Diseases Association, the Lupus Foundation of America, and the Lupus Research Alliance.

We acknowledge the following for their financial support in helping to make this initiative possible: Aurinia Pharmaceuticals, the Biotechnology Innovation Organization (BIO), Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Genentech, GlaxoSmithKline and Company, Mallinckrodt Pharmaceuticals and UCB.